ASX / Media Release Immutep Quarterly Activities Report & Appendix 4C Q1 FY27 • Immutep intends to focus the registration-directed clinical development of efti on HNSCC in patients with CPS
Immutep Quarterly Activities Report and Appendix 4C
Filed with ASX ·
6ix is reading this filing.
Story so far
Earlier from Immutep
- Immutep Receives A$2.16 million French R&D Tax Incentive
- Immutep Receives ~A$0.86 Million R&D Tax Incentive
- Change to American Depositary Share Ratio
- Immutep Outlines Focused Development Strategy for Eftilagimod Alfa (“efti”)
- Immutep Outlines Focused Development Strategy for Efti
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep